News Archives - CannabisNewsWire

ThursdayApr 25, 2024 1:01 pm

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH), Subsidiary Establish Four-Pillar Business Model to Ensure Successful Development of Destino Ranch

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, and its wholly owned subsidiary, Lavish Entertainment (or “Lavish”), have developed a comprehensive four-pillar business model. According to the announcement, the company intends for this key business component to be a critical component moving forward as Lavish Entertainment focuses on creating an industry-leading entertainment business. Specifically, the business model will be used as the company’s flagship project, Destino Ranch, is being developed. The new business model includes four essential key foundational elements: logistics, staffing, equipment and production. The company noted that these specific pillars were carefully identified and organized to complement…

WednesdayApr 24, 2024 2:52 pm

CannabisNewsBreaks – Software Effective Solutions Corp.’s (SFWJ) Eko2o S.A.S. Marks Significant Step in Strategy to Increase Global Footprint

Eko2o S.A.S., a pioneering force in agricultural technology and infrastructure and a majority-controlled subsidiary of Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), today announced its continued growth and expansion as a key infrastructure supplier for some of Colombia’s largest flower producers. In addition, the company announced it is enhancing its support and sales operations with international partnerships, notably with Danziger International, one of the flower industry’s most respected names. According to the announcement, the expanding partnership with Danziger International marks a significant step in Eko2o’s strategy to increase its global footprint and is expected to boost Eko2o’s visibility on the…

TuesdayApr 23, 2024 2:33 pm

CannabisNewsBreaks – Zoned Properties Inc. (ZDPY) Announces $1M Stock Repurchase Program

Zoned Properties (OTCQB: ZDPY), a leading real estate development firm for emerging and highly regulated industries including legalized cannabis, today announced that its board of directors has approved a share repurchase program, pursuant to which the company is authorized to purchase up to $1 million of its common stock over an unlimited time period. “As our business continues to outperform in a challenging overall operating environment, we are thrilled to announce this share repurchase program. The approval of this program demonstrates the management team’s and board’s confidence in our prospects for the future, ongoing operational strength and sound capital structure,”…

ThursdayApr 18, 2024 2:18 pm

CannabisNewsBreaks – Zoned Properties Inc. (ZDPY) Featured in Bell2Bell Podcast

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, was featured in the latest episode of the Bell2Bell Podcast as part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Bryan McLaren, chairman and CEO of Zoned Properties, joined the program to provide an overview of the company’s business model and how his experience translates into the regulated cannabis space. “Zoned Properties, based in Scottsdale, Arizona, is focused on real estate and the regulated cannabis industry. Zoned Properties is essentially a technology-driven property investment company. We look at state-by-state markets…

ThursdayApr 18, 2024 1:56 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (“SAB”). The announcement noted that the addition reinforces the company’s commitment to advancing its INM-901 program in the treatment of Alzheimer’s disease. Dr. Morgan is the Director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. His research interests are Alzheimer’s disease, aging and brain function. “We are privileged to welcome someone of Dr. Morgan’s…

WednesdayApr 17, 2024 3:39 pm

CannabisNewsBreaks – BizCann Expo Colombia to Showcase Insights on Emerging Trends in Canna-Business Landscape

The BizCann Expo, produced and hosted by ZJ Events, today announced the next rendition of its premier cannabis confab. Set to take place at the sleek Plaza Mayor in Medellin, Colombia, from May 18-19, the expo follows a series of blowout events in both North and South America. BizCann Expo is among the world’s elite business and networking events, leading industry innovation, entrepreneurship and education across all aspects of the cannabis industry. BizCann Expo provides novices as well as established players in the canna-business arena the ideal platform to elevate ventures and services in this burgeoning sector. This year’s event…

TuesdayApr 16, 2024 3:42 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received approval to begin a new human pilot study. The approval, which was granted by an independent third-party ethics review board, enables Lexaria to move forward with its plan to conduct a GLP-1 study investigating GLP-1 drugs and DehydraTECH(TM). According to the announcement, subject recruitment will begin immediately with the first dosing expected within the next month; the company plans to complete the study this summer. The study will be comprised of two study arms and will include up to nine healthy volunteers. The study is designed to…

TuesdayApr 16, 2024 1:31 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). The reported data continues to demonstrate positive pharmacological effects in the treatment of dry age-related macular degeneration (“AMD”). According to the announcement, in vivo preclinical studies in AMD disease models show that INM-089 delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement. Earlier results showed that INM-089 also preserved retinal function…

ThursdayApr 11, 2024 11:06 am

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH), Lavish Entertainment Announce Acquisition, Strengthen Position as ‘Powerhouse’ in Entertainment Space

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, and its wholly owned subsidiary, Lavish Entertainment, have closed on the full acquisition of ABI Create, a premier event-management and production company. ABI Create was founded in 2015 by Lavish Entertainment president and COO Marco Antonio Moreno. Since its inception, ABI Create has established a reputation for delivering high-quality productions for a range of large-scale installations at major music festivals, sporting events and conventions. The company has partnered with the NFL Super Bowl, San Diego and New York Comic Con events, EDC and Camp EDC, Bonnaroo Music Festival, the Waste Management…

ThursdayApr 04, 2024 2:23 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data demonstrating the positive effects of its INM-901 for the potential treatment of Alzheimer's disease ("AD"). Highlights of the report note that INM-901 receptor binding studies indicate preferential signaling agonism for both cannabinoid 1 (“CB1”) and cannabinoid 2 (“CB2”) and impacts the peroxisome proliferator-activated receptors (“PPAR”) signaling pathway while in vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function. In addition, molecular analysis data explains previously reported observations in behavioral studies on locomotion, memory and cognition. According…

News and publishing service for cannabis related companies

Contact us: 303.498.7722

Breaks Categories: News